WAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/zgen) is investigating potential claims against the board of directors of ZymoGenetics, Inc. ("ZymoGenetics" or the "Company") (NASDAQ: ZGEN) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell ZymoGenetics to Bristol-Myers Squibb Company.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of ZymoGenetics. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/zgen.
Under the terms of the announced tender offer, ZymoGenetics shareholders will receive $9.75 in cash for each share of ZymoGenetics they own if the tender offer is completed. The companies expect the tender offer to close approximately thirty days after commencement of the tender offer on or about September 9, 2010.
If you own shares of ZymoGenetics and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/zgen. You may also email Mr. Maniskas at firstname.lastname@example.org. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.